Vyrix Pharmaceuticals, a biotech developing an oral treatment for premature ejaculation, withdrew its plans for an initial public offering on Monday citing market conditions. The company originally filed for a $30 million IPO in April 2014.
The company is owned by Ampio Pharmaceuticals (NYSEMKT: AMPE). A female sexual dysfunction biotech, S1 Biopharma (SXB), had set terms to raise $36 million earlier this month but postponed its offering.
The Greenwood Village, CO-based company was founded in 2013. VYRX. Aegis Capital and Fordham Financial Management were set to be the joint bookrunners on the deal.
